SELLAS Life Sciences Group Inc. (SLS)

1.59 -0.06 (-3.636%)

IEX Real-Time Price

11:17:30 AM EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.65

Price Open 1.74

Volume: 313,433

Avg Volume: 3.4M

Market Cap: 35.02M

P/E Ratio -0.89

52 Wk Range 0.8001-12.006



SLS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
17.52M
1.08M
0.84
6.16%

2018-09-28
17.52M
761,271
1.43
4.35%

2018-09-14
17.52M
837,290
1.85
4.78%

2018-08-31
17.52M
791,101
1.94
4.52%




SLS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-15
Q2 2018
N/A
-1.08 (1)
-1.26
-0.18

2018-07-04
Q1 2018
N/A
0.00 (1)
0.00
0.00

2018-06-20
Q1 2018
N/A
-0.93 (1)
0.00
0.00

2018-05-09
Q1 2018
N/A
-0.93 (1)
0.00
0.00

News

SELLAS Life Sciences Group, Inc. (SLS) CEO Angelos Stergiou on Q3 2018 Results - Earnings Call Transcript (2018-11-15 12:46 SeekingAlpha)

SELLAS Life Sciences Group, Inc. (SLS) Q3 2018 Results Earnings Conference Call November 15, 2018, 08:00 AM ET Executives Will OConnor - Investor Contact, Stern Investor Relations, Inc. Angelos Stergiou - President and Chief Executive Officer Gene Mack - Chief Financial O…

 

RBS, LYG and BCS among premarket losers (2018-11-15 09:18 SeekingAlpha)

CDTi Advanced Materials (NASDAQ: CDTI ) -61% on Q3 earnings . More news on: Clean Diesel Technologies, Inc., Pyxis Tankers Inc., RYB Education, Stocks on the move, , Read more …

 

SELLAS Life Sciences down 3% on Q3 result (2018-11-15 08:34 SeekingAlpha)

SELLAS Life Sciences ( SLS +1% ) Q3 results : Revenues: $0; R&D Expense: $1.7M (+54.5%); SG&A: $1.3M (-59.4%); Net Loss: ($9.4M) (-108.9%); Loss Per Share: ($0.53) (+76.7%); Quick Assets: $10M; CF Ops: ($25.9M). More news on: SELLAS Life Sciences Group, Inc., Healthcare stocks n…

 


Statistics

Shares Outstanding: 22.03M

Top 15 Institution Percent: 5.70

Price To Sales: N/A

Price To Book: 1.97

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -84.91

Return On Equity: -225.96

Profit Margin: N/A

Price History

Beta: 1.04

50-day Moving Avg: 1.43

200-day Moving Avg: 3.42

YTD Change: -75.39

5-day Change: -20.29

1-month Change: 5.77

3-month Change: 101.66

6-month Change: -70.32

1-year Change: -81.54

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: SELLAS Life Sciences Group Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.